Previous Close | 0.1000 |
Open | 0.1000 |
Bid | 0.1500 |
Ask | 0.2000 |
Strike | 2.50 |
Expire Date | 2024-06-21 |
Day's Range | 0.0500 - 0.1500 |
Contract Range | N/A |
Volume | |
Open Interest | 6.29k |
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.